FOR IMMEDIATE RELEASE
KNOXVILLE, TN, July 24, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing
clinical trial of PV-10 for the treatment of symptomatic metastatic neuroendocrine tumors of the liver (NCT02693067) will be presented in a poster presentation at the ESMO 2018 Congress (the European
Society for Medical Oncology annual meeting), held in Munich, Germany from October 19-23, 2018.
The presentation is entitled “A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using
Intralesional Rose Bengal Disodium.”
Details regarding the presentation will be announced closer to the ESMO 2018 Congress.
About Neuroendocrine Tumors
Neuroendocrine tumors (NETs) associated with the gastrointestinal tract have endocrine secretory properties and a
propensity for metastasis to the lungs, bronchi, and liver. Metastatic neuroendocrine tumors located in the midgut and liver often
secrete vasoactive products, giving rise to symptoms such as flushing and diarrhea, wheezing, abdominal cramps, and peripheral
oedema.
About PV-10
Provectus’ lead investigational oncology drug product, PV-10, the first small molecule oncolytic immunotherapy,
can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor
cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company leading the
development of a new class of drugs based on halogenated xanthenes. Information about the Company’s clinical trials can be found at
the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's
website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” as defined under U.S. federal securities
laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express
management's current views of future performance, results, and trends and may be identified by their use of terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar
terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking statements. Readers should not place undue reliance on
forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such
statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking
statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A
of our Annual Report on Form 10-K for the year ended December 31,
2017).
Contact: Provectus Biopharmaceuticals, Inc. Tim Scott, Ph.D. President Phone: (866) 594-5999
